Acute myeloid leukemia (AML) is type of blood and bone marrow cancer characterized by abnormal production of myeloid blasts in the bone marrow and peripheral blood. Rising incidence of AML, higher number of unmet needs, expected launch of ideal molecules and technological advances are prime factors that driving the growth of AML therapeutics market globally.
Kaposi sarcoma is caused due to the infection of a virus called as Kaposi sarcoma associated herpes virus (KSHV). The disease prevalence is varied around the globe; there are four types of Kaposi sarcoma such as AIDS-KS, immunocompromised, classic or sporadic and endemic. Technological advancement in the drug delivery such as targeted immunotherapy and nanomedicines are utilized to facilitate the cytotoxic payload through the blood vessels in the Kaposi sarcoma tumors which usually develops from the cells that line the lymph or blood vessels.
The report titled “Cancer Biomarkers Market- Growth, Future Prospects, and Competitive Analysis, 2017 – 2025” offers strategic insights into the overall cancer biomarkers market along with the market size and estimates for the duration 2015 to 2025. The said research study cover in-depth analysis of multiple market segments based on type, type of cancer, type of profiling technologies, type of application, and different geographies.
Kidney cancer is the most common cancer in the world around 63,990 new cases are estimated to be in 2017. Among the primary kidney cancer, renal parenchymal cancer is the most common estimating around 80-90% and it is the most complex to treat. The chances of developing cancer is about 1 in 63 in lifetime, with higher risk in men than women.
The report titled “Umbilical Cord Blood Banking Market- Growth, Future Prospects, and Competitive Analysis, 2017 – 2025” offers strategic insights into the overall umbilical cord blood banking market along with the market size and estimates for the duration 2015 to 2025.
Intracranial pressure monitors are an integral part of neurological surgery for monitoring and recording the pressure inside the head and skull as increased intracranial pressure can be life-threatening. Severe brain injury, brain trauma, tumors, hydrocephalus, meningitis, stroke and other neurological conditionsmay lead to elevated intracranial pressure, which needs to get detected to prevent further injury to nervous system.
Glycomics or glycobiology is the study of the structure, function, biosynthesis, and biology of carbohydrates, often called glycans that are widely distributed in nature. Increasing applicability of glycobiology in biotechnology and pharmaceutical industries, growing number of biopharmaceutical industries and rising research institutes are major factors that assist the growth of glycobiology market globally.
Cell signaling is a complex process of communication, which governs basic activities of cells and coordinates cell actions. Factors such as growing applicability of cell signaling in biotechnology and medical industries, advancements in cell-based research technology, growing number of biopharmaceutical industries and wide availability advance cell signaling are driving the growth of cell signaling market globally.
This report on global molecular diagnostics market studies various products, applications and technologies used in the field of molecular diagnostics. Increasing number of patients suffering with chronic illnesses requiring prompt diagnosis, rising demand for personalized medication, advent of pharmacogenomics and government initiatives in promoting public health and welfare will propel the molecular diagnostics market.
Advanced endoscopy is used for inserting stents into several sites of the gastrointestinal tract and the procedure has proved to be a significant therapeutic development. Stents assist in opening strictured areas in the esophagus, duodenal region, colon and the biliary tree. Stents efficiently overcome the structuring associated with benign formations and cancer and are also used as a palliation of obstructive symptoms, and other obstructions in the GI tract.
The oncology drugs market includes pharmaceutical products and advanced therapies used to treat cancer. Major treatment classes include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, antibody-drug conjugates, cancer vaccines and cell-based treatments. These drugs are used across lung, breast, colorectal, prostate, blood, skin, ovarian, liver and other cancer indications.
The global cancer and oncology drugs market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 214.70 billion in 2026 to USD 554.69 billion by 2035, representing a compound annual growth rate of 11.17%. Growth is supported by targeted treatments, developments in proteomics and continued demand for more effective cancer therapies.
The increasing global incidence of cancer is a major market driver. Population ageing, tobacco use, obesity, environmental exposure and lifestyle-related risk factors are contributing to a growing patient population. Improved screening and diagnostic technologies are also identifying more patients at earlier stages, increasing the number of individuals eligible for pharmaceutical treatment.
Targeted therapies represent an important market segment. These drugs act on specific genes, proteins or pathways involved in tumour development. Biomarker testing and companion diagnostics help physicians identify patients who are more likely to respond to particular treatments. Precision oncology is therefore increasing the connection between diagnostic testing and drug selection.
Immunotherapy continues to change cancer treatment by helping the immune system identify and attack tumour cells. Immune checkpoint inhibitors, CAR-T cell therapies and cancer vaccines are being studied across multiple solid and blood cancers. Combination therapies using immunotherapy with chemotherapy, targeted drugs or radiation are also expanding as companies seek to improve treatment response and patient survival.
Other major trends include antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and personalized cancer vaccines. Artificial intelligence is being used for target identification, molecule screening, clinical-trial planning and analysis of patient data. Biosimilars are gaining importance as patents expire for established oncology biologics, potentially improving access and increasing price competition.
Market expansion may be restrained by high treatment costs, adverse effects and unequal access to cancer care. Oncology drugs require extensive clinical testing, and unsuccessful trials can result in substantial development losses. Drug resistance may reduce long-term treatment effectiveness and create demand for additional therapies. Reimbursement restrictions and complex regulatory requirements can also delay patient access.
North America remains a major market due to high cancer treatment expenditure, research activity and access to new medicines. Europe maintains a significant position, while Asia-Pacific is expected to record strong growth as cancer incidence, healthcare investment and access to treatment increase.
Acute Market Reports provides oncology drugs market research covering drug classes, cancer indications, routes of administration, distribution channels, development pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, investors and healthcare organizations assess market demand and growth prospects through 2035.